Evidence map›Paper›PMID 37532918›Full record

ArticleActa parasitologica2023

Fatal Disseminated Strongyloidiasis in an Immunosuppressed Patient During COVID-19 Pandemic.

Eissa Soleymani, Lotfollah Davoodi, Shadi Shayesteh Azar, Seyed Reza Mirbadiei, Fatemeh Parandin, Afshin Azimi, Azadeh Mizani, Zohreh Khorshidvand, Mahdi Fakhar

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Acta parasitologica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Eissa Soleymani *Department of Infectious Diseases, Faculty of Medicine, Antimicrobial Resistance Research Center, Mazandaran University of Medical Sciences, Sari, Iran.
Lotfollah Davoodi *Department of Infectious Diseases, Faculty of Medicine, Antimicrobial Resistance Research Center, Mazandaran University of Medical Sciences, Sari, Iran.
Shadi Shayesteh AzarDepartment of Infectious Diseases, Faculty of Medicine, Antimicrobial Resistance Research Center, Mazandaran University of Medical Sciences, Sari, Iran.
Seyed Reza MirbadieiDepartment of Parasitology and Mycology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
Fatemeh ParandinResearch Center for Environmental Determinants of Health (RCEDH), Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Afshin AzimiDepartment of Parasitology and Mycology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
Azadeh MizaniDepartment of Parasitology, Pasteur Institute of Iran, Tehran, Iran.
Zohreh KhorshidvandDepartment of Parasitology and Mycology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
Mahdi FakharIranian National Registry Centre for Lophomoniasis and Toxoplasmosis, Imam Khomeini Hospital, Mazandaran University of Medical Sciences, P.O Box: 48166-33131, Sari, Iran. mahdifakhar53@gmail.com.
Mazandaran University of Medical Sciences · IRHamedan University of Medical Sciences · IRKermanshah University of Medical Sciences · IRPasteur Institute of Iran · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThis report presents a fatal case of disseminated strongyloidiasis in a patient with myasthenia gravis and diabetes mellitus who had received corticosteroid therapy. CASE REPORT: The patient was a 67-year-old woman living in a rural area endemic for Strongyloides stercoralis in northern Iran. Disseminated strongyloidiasis was diagnosed in the advanced stage of the disease, with enormous numbers of larvae demonstrated in direct smears prepared from stool samples and stomach biopsy. Despite treatment with ivermectin and antibiotics, the patient succumbed to the severity of the infection.

conclusionClinicians working in endemic areas should be mindful of the possibility of gastric involvement in strongyloidiasis, even if symptoms are nonspecific. We recommend that high-risk individuals be screened for S. stercoralis prior to immunosuppressive therapy in endemic regions to raise awareness and prevent similar cases.

Indexed as

COVID-19Strongyloides stercoralisStrongyloidiasisAgedAnimalsFemaleHumansIvermectinPandemicsIvermectinDisseminated strongyloidiasisImmunosuppressive therapyMyasthenia gravisStrongyloides stercoralis

Identifiers

PMID37532918
OpenAlexW4385488140

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.